Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs

Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs Drug Saf (2017) 40:757–760 DOI 10.1007/s40264-017-0549-7 COMMENTARY Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs Malcolm Maclure Published online: 3 June 2017 Springer International Publishing Switzerland 2017 Decades after the case-crossover (CCO) design was first between-person confounding in creating the simulated data described [1], recent studies of potential biases and alter- for realistic methodologic studies of traditional cohort and native applications of CCO analyses using pharmaceutical case–control designs [7]. However, much, if not all, of that and healthcare utilization databases are still yielding new between-person confounding would be automatically insights [2, 3]. In this issue of Drug Safety, Burningham eliminated from CCO analyses because cases serve as their et al. [4] report their assessments of the performance of own controls. Ironically, the main strength of OSIM2 as a CCO methods for studying more chronic effects of drugs, creator of simulation data might thus be negated by the similar to the work of Schuemie et al. [5] on studying long- main strength of the CCO design. term effects of accumulated exposures using the self-con- OSIM2 was not explicitly designed to produce realistic trolled case-series (SCCS) method. within-person confounding in the simulated data. Murray Based http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Drug Safety Springer Journals

Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs

Drug Safety , Volume 40 (9) – Jun 3, 2017

Loading next page...
 
/lp/springer_journal/using-simulated-data-to-assess-case-crossover-designs-for-studying-kZ5nnV2mty

References (10)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-5916
eISSN
1179-1942
DOI
10.1007/s40264-017-0549-7
pmid
28578518
Publisher site
See Article on Publisher Site

Abstract

Drug Saf (2017) 40:757–760 DOI 10.1007/s40264-017-0549-7 COMMENTARY Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs Malcolm Maclure Published online: 3 June 2017 Springer International Publishing Switzerland 2017 Decades after the case-crossover (CCO) design was first between-person confounding in creating the simulated data described [1], recent studies of potential biases and alter- for realistic methodologic studies of traditional cohort and native applications of CCO analyses using pharmaceutical case–control designs [7]. However, much, if not all, of that and healthcare utilization databases are still yielding new between-person confounding would be automatically insights [2, 3]. In this issue of Drug Safety, Burningham eliminated from CCO analyses because cases serve as their et al. [4] report their assessments of the performance of own controls. Ironically, the main strength of OSIM2 as a CCO methods for studying more chronic effects of drugs, creator of simulation data might thus be negated by the similar to the work of Schuemie et al. [5] on studying long- main strength of the CCO design. term effects of accumulated exposures using the self-con- OSIM2 was not explicitly designed to produce realistic trolled case-series (SCCS) method. within-person confounding in the simulated data. Murray Based

Journal

Drug SafetySpringer Journals

Published: Jun 3, 2017

There are no references for this article.